UK markets closed

Quantum Genomics Société Anonyme (QNNTF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.10100.0000 (0.00%)
At close: 10:40AM EDT

Quantum Genomics Société Anonyme

33 rue Marbeuf
Paris 75008
France
33 1 85 34 77 70
https://www.quantum-genomics.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees3

Key executives

NameTitlePayExercisedYear born
Dr. Jean-Philippe Milon Ph.D.CEO, MD & Chairman450.41kN/A1960
Mr. Benoît GueugnonAdministrative & Financial Director, VP of Finance and CFON/AN/AN/A
Dr. Bruno BesseChief Medical OfficerN/AN/AN/A
Dr. Sarah Merlen-BoulengerHead of Regulatory AffairsN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs. The company also is involved in the development of drugs for the treatment of high blood pressure as monotherapy and the prevention, as well as treatment of heart failure. Quantum Genomics Société Anonyme was incorporated in 2005 and is based in Paris, France.

Corporate governance

Quantum Genomics Société Anonyme’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.